355 related articles for article (PubMed ID: 25633150)
1. Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity.
van den Bergen JC; Wokke BH; Hulsker MA; Verschuuren JJ; Aartsma-Rus AM
Neuromuscul Disord; 2015 Mar; 25(3):231-7. PubMed ID: 25633150
[TBL] [Abstract][Full Text] [Related]
2. Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity.
Sewry CA
Neuromuscul Disord; 2015 Jun; 25(6):530. PubMed ID: 25891277
[No Abstract] [Full Text] [Related]
3. Response to: Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity.
van den Bergen J; Aartsma-Rus A
Neuromuscul Disord; 2015 Jun; 25(6):530-1. PubMed ID: 26004424
[No Abstract] [Full Text] [Related]
4. [Association between dystrophin and neuronal nitric oxide synthase in muscles of progressive muscular dystrophy].
Wang S; Shen D
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):155-7. PubMed ID: 11953148
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
Janghra N; Morgan JE; Sewry CA; Wilson FX; Davies KE; Muntoni F; Tinsley J
PLoS One; 2016; 11(3):e0150818. PubMed ID: 26974331
[TBL] [Abstract][Full Text] [Related]
6. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions.
Torelli S; Brown SC; Jimenez-Mallebrera C; Feng L; Muntoni F; Sewry CA
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):540-5. PubMed ID: 15488030
[TBL] [Abstract][Full Text] [Related]
7. Dystrophin R16/17 protein therapy restores sarcolemmal nNOS in trans and improves muscle perfusion and function.
Zhao J; Yang HT; Wasala L; Zhang K; Yue Y; Duan D; Lai Y
Mol Med; 2019 Jul; 25(1):31. PubMed ID: 31266455
[TBL] [Abstract][Full Text] [Related]
8. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice.
Li D; Long C; Yue Y; Duan D
Hum Mol Genet; 2009 Apr; 18(7):1209-20. PubMed ID: 19131360
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry of sarcolemmal membrane-associated proteins in formalin-fixed and paraffin-embedded skeletal muscle tissue: a promising tool for the diagnostic evaluation of common muscular dystrophies.
Suriyonplengsaeng C; Dejthevaporn C; Khongkhatithum C; Sanpapant S; Tubthong N; Pinpradap K; Srinark N; Waisayarat J
Diagn Pathol; 2017 Feb; 12(1):19. PubMed ID: 28219397
[TBL] [Abstract][Full Text] [Related]
10. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.
Li D; Bareja A; Judge L; Yue Y; Lai Y; Fairclough R; Davies KE; Chamberlain JS; Duan D
J Cell Sci; 2010 Jun; 123(Pt 12):2008-13. PubMed ID: 20483958
[TBL] [Abstract][Full Text] [Related]
11. Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice.
Hoyte K; Jayasinha V; Xia B; Martin PT
Am J Pathol; 2004 Feb; 164(2):711-8. PubMed ID: 14742274
[TBL] [Abstract][Full Text] [Related]
12. Dystrophin, utrophin and beta-dystroglycan expression in skeletal muscle from patients with Becker muscular dystrophy.
Kawajiri M; Mitsui T; Kawai H; Kobunai T; Tsuchihashi T; Saito S
J Neuropathol Exp Neurol; 1996 Aug; 55(8):896-903. PubMed ID: 8759779
[TBL] [Abstract][Full Text] [Related]
13. Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice.
Peter AK; Miller G; Crosbie RH
J Cell Sci; 2007 Mar; 120(Pt 6):996-1008. PubMed ID: 17311848
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for Duchenne and Becker dystrophies.
Voisin V; de la Porte S
Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment.
Assereto S; Stringara S; Sotgia F; Bonuccelli G; Broccolini A; Pedemonte M; Traverso M; Biancheri R; Zara F; Bruno C; Lisanti MP; Minetti C
Am J Physiol Cell Physiol; 2006 Feb; 290(2):C577-82. PubMed ID: 16192300
[TBL] [Abstract][Full Text] [Related]
16. Dystrophin-associated protein abnormalities in dystrophin-deficient muscle fibers from symptomatic and asymptomatic Duchenne/Becker muscular dystrophy carriers.
Di Blasi C; Morandi L; Barresi R; Blasevich F; Cornelio F; Mora M
Acta Neuropathol; 1996 Oct; 92(4):369-77. PubMed ID: 8891069
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.
Chaubourt E; Fossier P; Baux G; Leprince C; Israël M; De La Porte S
Neurobiol Dis; 1999 Dec; 6(6):499-507. PubMed ID: 10600405
[TBL] [Abstract][Full Text] [Related]
18. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura P; Jasmin BJ
Trends Mol Med; 2006 Mar; 12(3):122-9. PubMed ID: 16443393
[TBL] [Abstract][Full Text] [Related]
19. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
20. A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.
Sewry CA; Nowak KJ; Ehmsen JT; Davies KE
Neuromuscul Disord; 2005 Nov; 15(11):779-85. PubMed ID: 16198105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
